Israel’s DreaMed Diabetes (see here previously) has received FDA approval for its MODI system. MODI uses glucose-monitoring data to automatically optimize insulin dosing for people with type 2 diabetes across both basal-only (steady regulation) and bolus (booster) insulin regimens.
https://dreamed.ai/press-releases/dreamed-receives-fda-clearance-for-modi/